Randomized phase II trial of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with KRAS wild metastatic colorectal cancer refractory to oxaliplatin and bevacizumab with translational research to predict efficacy.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Bevacizumab (Primary) ; Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 29 Aug 2016 Status changed from recruiting to completed according to results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 12 Mar 2011 New trial record